Biologix Hair Inc. Reports Strong Initial Clinician Licensing Numbers

Biologix Hair Inc. Reports Strong Initial Clinician Licensing Numbers 
TORONTO, ONTARIO -- (Marketwire) -- 02/07/13 -- Biologix Hair Inc.
(OTCBB:BLGX)(OTCQB:BLGX) is pleased to report the Company's clinician
licensing results as of January 31st, 2013. 
Biologix Hair's worldwide Clinician Licensing Department,
headquartered in Toronto, Canada, has contracted on behalf of
Biologix with 121 medical services clinics located in six different
countries, which have reserved certain exclusive purchase and
treatment rights for the Biologix Hair Therapy System(TM) and to be
licensed as certified Biologix Hair Therapy Centers(TM). 
Based on information provided by the contracting clinics, the total
number of existing patients represented by these 121 clinics is
372,440, of which the clinicians estimate approximately 205,919 will
be interested in the patent-pending Biologix Hair Therapy System(TM),
if and when FDA and other market approvals are forthcoming. 
Donna Lieder, Biologix Vice President of Clinician Licensing, stated,
"I am very pleased with the successful launch of our effort to build
a global network of licensed medical practitioners seeking to become
Certified Biologix Hair Therapists(TM) and secure exclusive
territorial purchasing and treatment rights for the Biologix Hair
Therapy System(TM). The receptivity we have received within the
medical community has been overwhelmingly positive and is a strong
indication of how much potential demand exists for our unique,
patent-pending treatment. 
"Keeping in mind that the numbers cited above are estimates based
only on the clinicians' existing number of patients and do not
include any forecasts related to potential new patients within their
respective territories who may be interested in the Biologix Hair
Therapy System(TM), there appears to be significant upside elasticity
in the markets being represented by these 121 clinics," continued
Here is what a couple of the contracting clinicians had to say about
why they decided to join the certified Biologix Hair Therapy
Center(TM) team: 
Danielle Brenza, Director of Operations for the Ageless Skin and
Laser Center in Sewell, New Jersey said, "I believe this innovative
technology will be ground-breaking for patients suffering with hair
t M. Gunderson, Director of Medical Services for the Hair
Restoration Institute of Pennsylvania said, "For us at HRI, wanting
to be the first with a Biologix territory was a no-brainer. As one of
the only true hair restoration clinics in Pittsburgh and the
surrounding area, we are constantly striving to give our current and
future clients the very 'latest and greatest' breakthroughs when it
comes to hair restoration. That's why we waited to buy a laser until
the FDA actually approved a salon laser (the MEP-90). We're the only
clinic in PA to have a true laser solution with clinical results, not
just cosmetic results. We waited to make sure we found a transplant
surgeon who was both board certified and experienced enough to have
the respect of his peers. We take our business and its results
seriously and only want the best for our clients. After speaking with
Donna Lieder and better understanding what Biologix was doing, I
signed up immediately, and am excited every time I receive new mail
about Biologix. 
"Biologix is poised to become the leader in hair restoration... HRI
is poised to be the best comprehensive solution provider to an ever
growing hair loss industry, and we are excited about having yet
another real and proven solution for our current and future clients,"
continued Gunderson. 
The breakdown of the 121 clinics by location is as follows:  

--  Bahamas (1) 
--  Canada (9 in 6 provinces): Alberta (3), British Columbia (1), Manitoba
    (1), New Brunswick (1), Nova Scotia (1) and Ontario (2) 
--  Cayman Islands (1) 
--  Philippines (1) 
--  Turks and Caicos (1) 
--  United States (108 in 31 states): Arkansas (1), Arizona (1), Colorado
    (1), California (21), Connecticut (2), Florida (6), Georgia (7), Indiana
    (4), Illinois (3), Kentucky (1), Maryland (1), Massachusetts (5),
    Michigan (3), Minnesota (3), Nebraska (1), New Jersey (2), New Mexico
    (1), New York (7), Nevada (2), Ohio (6), Oklahoma (1), Oregon (1),
    Pennsylvania (1), Rhode Island (2), Tennessee (1), Texas (10), Virginia
    (2), Washington (7), West Virginia (1), Wisconsin (1) and Wyoming (2). 

Ron Holland, Biologix Director and CEO, stated, "Building out a
worldwide distributor network for our proprietary hair formula is an
essential part of our Company's business plan. As we continue to
pursue FDA and other regulatory approvals following our current
research program underway with the Beijing Institute of Technology,
we intend to maximize the immediacy of our potential to generate
revenues via this clinician distribution network. I am very pleased
with the great work Donna and her team have done to date and look
forward to reporting future numbers as they materialize and the
network expands." 
About Biologix Hair Inc. and Biologix Hair Science Ltd. 
Biologix Hair Inc. (Biologix Hair), together with its wholly owned
biotechnology subsidiary, Biologix Hair Science Ltd. (TM) (BHS), is
focused on realizing the full market potential for its patent-pending
hair loss formula - Biologix Revive - and its demonstrated ability to
prevent and reverse the effects of alopecia, which plagues hundreds
of millions worldwide. 
Between mid-2004 and mid-2012, more than 30,000 pre-clinical-trial
treatments of Biologix Revive were administered to 5,000-plus
patients in South America suffering with varying degrees of alopecia,
as well as people seeking preventive treatment. The participating
treatment clinicians subjectively observed and reported that
virtually 100% of preventive care clients continued to retain their
healthy hair and an estimated 80-85% of the males and 90-plus% of the
females treated for hair regeneration experienced significant
regrowth of their own natural hair. And among alopecia areata
patients, virtually total hair regrowth was observed in 100% of the
cases. To date, no negative side effects have been reported. 
BHS is currently focused on obtaining FDA approval for its
breakthrough hair loss prevention and regeneration therapy and has
initiated a research and development program with one of the world's
leading medical research universities, the Beijing Institute of
Technology (BIT). The R&D program, expected to take approximately
twelve months to complete, is an important final step before formal
clinical trials and the FDA approval process begins. 
Additionally, on May 11, 2012, Venable LLP, the Washington-based law
firm overseeing the worldwide IP and regulatory approval processes on
behalf of BHS, filed a Patent Cooperation Treaty (PCT) application on
behalf of BHS for Biologix Revive in Geneva, Switzerland. The PCT is
an international treaty, administered by the World Intellectual
Property Organization (WIPO), to which 144 countries have as of now
contracted, including Canada and the United States. 
Biologix management is determined to be in a ready position to
capitalize on the high-margin sales potential of the Biologix Hair
Therapy System(TM), if and when FDA and other major market approvals
are forthcoming. 
As BHS advances the regulatory approval process, Biologix Hair,
together with wholly owned subsidiary companies operated by BHS, are
rapidly developing a global distribution network of licensed
clinicians and medicalpractition
ers seeking to become Certified
Biologix Hair Therapists(TM) and secure exclusive territorial
purchasing and treatment rights for the Biologix Hair Therapy
Biologix Hair has decided not to risk creating any potential
regulatory conflicts by offering treatment outside the United States
and other major high-product-margin markets until FDA approval has
been granted. Therefore, the Biologix Hair Therapy System(TM) is not
yet available other than to the 5,000+ patients who participated in
the pre-clinical trials conducted in South America. 
To learn more about Clinician Licensing opportunities, Click Here or
call toll free +1 855.737.0333 or +1 647.344.5900. 
This announcement is not an offer to sell any Biologix Hair Inc.
("Biologix") securities. Offers for any given security are made only
through applicable offering circulars and related documents filed
with the SEC pursuant to the Securities Act of 1933 or the Securities
Exchange Act of 1934. Certain statements contained herein and
subsequent oral statements made by and on behalf of Biologix may
contain "forward-looking statements". Such forward-looking statements
are identified by words such as "intends", "anticipates", "believes",
"expects" and "hopes" and includes, without limitation, the
development of treatment centers and approval from regulatory
authorities. Forward-looking statements express our expectations or
predictions of future events or results. They are not guarantees and
are subject to many risks and uncertainties. There are a number of
factors beyond our control that could cause actual events or results
to be significantly different from those described in the
forward-looking statements. Any or all of our forward-looking
statements in this report or in any other public statements we make
may turn out to be wrong. We undertake no obligation to publicly
update or review any forward-looking statements, whether as a result
of new information, future developments or otherwise. In Canada,
Europe and the United States, the Biologix treatment is not approved
for use by Health Canada, EMA or the FDA. The company makes no
representations that it will receive Health Canada, EMA or FDA
To view the image associated with this press release, click the
following link:
Biologix Hair Inc.
Corporate Communications
Toll Free: +1 855.292.8585
Phone: +1 902.801.7920
Press spacebar to pause and continue. Press esc to stop.